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Abstract
Background: Failed back surgery syndrome (FBSS) refers 
to the condition where persistent pain is experienced by 
patients following back surgery. This condition is historically 
difficult to treat. Spinal cord stimulation (SCS) and its recent 
technical advances have opened the door to a promising 
treatment option for FBSS. However, critical appraisal of 
supporting and refuting data is necessary to identify the best 
patient population for this treatment modality.
Methods: In this systematic review, we review randomized 
controlled studies and cohort studies with matched controls 
to synthesize the data on the overall efficacy of spinal 
cord stimulation for FBSS. We further identify available 
data on outcome measurements based on working status, 
psychological status, smoking, sex, and race to provide 
insight on patient selection and identify needs for further 
research.
Results: The literature search identified 34 publications, of 
which 23 were excluded due to duplication and inclusion/
exclusion criteria, yielding a total of 11 publications for 
review. Seven out of eleven studies reviewed had sources 
of potential funding or affiliation bias. Three out of 4 studies 
with radiating leg pain relief as their primary outcome 
showed statistically significant improvement with SCS 
treatment, while 2 out of 5 studies with mixed radiating 
leg pain and axial back pain as the primary outcome 
showed statistically significant improvement with SCS.  All 
randomized controlled trials that included functional status 
and quality of life outcome measures showed improvement 
after SCS, though scales utilized in each study varied.  Six 
studies included work status as a patient descriptor with only 
three reporting inclusion of workers’ compensation patients. 
There was limited data on the effect of psychological status, 
smoking, sex or race on SCS outcomes based on the 
studies reviewed.
Conclusions: Evidence for the efficacy of SCS in FBSS is 
accumulating, with most studies demonstrating its efficacy 
especially for those patients with leg pain as the predom-
inant symptom. However, a significant weakness in the 
current data includes potential bias based on the funding 
source for most studies. Additionally, it is clear that SCS pro-
vides short-term benefit, yet there is no solid evidence that 
SCS provides any benefit beyond two years of implantation. 
Another major concern is the significant placebo effect, 
which makes the true therapeutic response difficult to judge. 
Introduction
Neuromodulation as a concept to treat medical ail-
ments has been documented for centuries [1]. Spinal 
cord stimulation (SCS) as a type of neuromodulation 
to treat pain was first developed by Dr. Norman Shealy 
more than 50 years ago when he implanted the first 
stimulator device in a cancer pain patient [2]. This is the 
direct translational practice of the gate control theory, 
which hypothesized that the activation of A• fiber me-
diated touch sensation in the spinal cord can inhibit C 
fiber mediated pain sensation [3]. However, the true 
mechanism of SCS is much more complex and has not 
been fully elucidated. For example, SCS directly inhibits 
spinothalamic pain pathways and affects upstream su-
praspinal inhibitory pathways to reduce pain. Further, 
it has been shown that SCS can change peripheral blood 
flow and may therefore affect pain by vasodilation and 
improvement of blood flow in specific cases [4]. Over 
the past several decades, there has been tremendous 
progress in both technological advances of this modality 
as well as research efforts to refine its target population 
and to validate its efficacy. In the face of the opioid ep-
idemic, this technology has further gained traction and 
public attention, especially in the population of patients 
that has traditionally been difficult to treat.
One chronic pain condition that has seen tremen-
dous research and positive outcomes with SCS is failed 
back surgery syndrome. Also called post-laminectomy 
syndrome, it describes the condition where persistent 
pain is experienced by patients following back surgery. 
The incidence of this condition has been found to be 
between 10-40% after lumbar back surgery [5,6]. The 
etiology of the persistent pain varies, including per-
sistent radicular pain from long-term nerve root injury 
not improved by surgery, re-stenosis of neuroforamens 
Further, it is increasingly important to focus future studies 
on refining patient populations to those that may best 
respond to both SCS therapy in general, as well as specific 
stimulation techniques.
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or central canals, facet disease after lumbar fixation, or 
pain from a persistent surgical scar. These patients typ-
ically do not experience much improvement with mul-
tiple conservative therapies such as oral medications, 
physical therapy, and various injections even prior to 
the back surgery. In these cases, persistent pain after 
back surgery can be exponentially difficult to manage.
In this paper, we will systematically review the 
scientific evidence behind spinal cord stimulation with 
a focus on patient selection considerations for the 
indication of failed back surgery syndrome.
Methods
A) Search Strategy
A literature search was conducted by the authors 
to identify randomized controlled trials and matched 
cohort-control studies analyzing the efficacy of SCS for 
the indication of FBSS or post-laminectomy syndrome. 
The search was conducted using PubMed, Ovid and 
MEDLINE. MeSH terms included [“failed back surgery 
syndrome” AND neuromodulation], [neuromodulation 
AND FBSS], [“failed back surgery syndrome” AND 
“spinal cord stimulation”], [FBSS AND “spinal cord 
stimulation”], and [“spinal cord stimulation” AND 
“post-laminectomy syndrome”]. Studies published 
between 1991 and 2018 were included. A total of 677 
studies were identified through a PubMed search. Four 
more studies were identified through the citations of 
relevant aforementioned studies. The studies were 
further narrowed by screening for clinical studies and 
removing duplicates. After applying the stated inclusion 
and exclusion criteria and removing two studies with 
missing data, 11 studies were ultimately included in our 
analysis (Figure 1).
 
Records identified through
database searching
(n = 677)
Additional records identified
through other sources
(n = 4)
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(n = 681)
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(n = 34)
Studies included in
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(systematic review)
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with reasons
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Figure 1: Flowchart of identified studies through a PubMed search.
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publications for review.
Summary of Efficacy
Pain
Of the 11 studies selected for review, five studies fo-
cused on axial or radiating pain relief as their primary 
outcome [8,12,15-17]. Four studies included only ra-
diating pain relief as their primary outcome, and two 
studies reported only axial pain relief as its primary out-
come [9,10,11,13,14,18].
Three out of 4 studies with radiating leg pain relief as 
their primary outcome showed statistically significant 
improvement with SCS treatment [10,13,14]. Kumar, et 
al.’s PROCESS study looked at the difference in leg pain 
relief between SCS and conventional medical manage-
ment (CMM) with a follow-up period of 6 months and 2 
years [10,14]. At 6 months, they found that 48% of the 
SCS cohort had achieved at least 50% leg pain reduction, 
while only 9% of the CMM cohort achieved the same 
goal (p < 0.0001) [14]. At 24 months, they found that 
37% of patients in the SCS cohort maintained at least 
50% leg pain reduction compared to 2% in the CMM 
group [10]. Schu, et al. compared the efficacy of burst 
stimulation, 500 Hz tonic stimulation and placebo [13]. 
At 3 weeks follow-up, they reported a statistically sig-
nificant improvement in mean NRS score for burst stim-
ulation (5.6 to 4.7) that was superior to other groups 
(500 Hz tonic stimulation (mean NRS = 7.10) and pla-
cebo (mean NRS = 8.3), p < 0.05). Finally, Turner, et al. 
compared 3 different cohorts of workers’ compensation 
patients - those randomized to SCS, pain clinic, or usual 
care [11]. In this study, success for each modality was 
defined as achieving all of the following: 1. at least 50% 
pain reduction, 2. at least a 2-point reduction on the 
Roland-Morris Disability Questionnaire score, and 3. re-
duction in daily opioid use. At 6 months follow-up, they 
concluded that SCS was more successful than the oth-
er modalities (SCS: 18% of cohort experienced success, 
Pain clinic: 3%, Usual care: 5%); however, at 12 and 24 
months they reported that there was no statistically sig-
nificant difference between groups.
Pain relief with respect to axial pain was the primary 
outcome in two studies [9,18]. North, et al. in June 2005, 
compared dual electrode to single electrode placement 
and showed that at the 2.3 year post-implantation 
follow-up, 53% of the study population had at least 50% 
pain relief with no difference between the number of 
electrodes used [18]. Statistical significance was not 
reported. Al-Kaisy, et al. compared various levels of high 
frequency stimulation and sham [9]. Baseline mean VAS 
for back pain was recorded as 7.75, while mean scores 
for sham, 1200 Hz, 3030 Hz, and 5882 Hz were 4.83, 4.51, 
4.57, and 3.22, respectively. The study demonstrated 
statistically significant reduction in VAS score across 
B) Selection Criteria
All RCTs and cohort-control studies were assessed 
for inclusion in this review by two authors. Studies 
without inclusion of FBSS patients were excluded, as 
were studies without controls. The Jadad Scale [7]. was 
used to assess the quality of each study.
Inclusion Criteria
1. Randomized controlled studies OR cohort studies 
with matching control.
2. Spinal cord stimulation studies for the indication of 
pain in post-laminectomy syndrome or failed-back 
surgery syndrome.
3. Studies with patient-related clinical primary or sec-
ondary outcomes.
Exclusion Criteria
1. Retrospective or non-controlled studies.
2. Spinal cord stimulation studies for the indication of 
other pain conditions or for non-pain conditions.
3. Studies that include other pain diagnoses in addition 
to FBSS but do not disaggregate outcome data by 
patient diagnosis.
4. Spinal cord stimulation studies that did not assess 
pain scores or measures of functional pain changes.
C) Outcomes Measured
Our measured outcomes were chosen according to 
common patient-related clinical outcomes reported in 
the reviewed studies as well as outcomes used in clinical 
decision making between the patient and physician. 
They include changes in:
- Perceived pain
- Analgesic use
- Quality of life
- Function
- Patient satisfaction
D) Summary Measures and Synthesis of Results
Each study used its own outcomes scales. As a 
result, there is a heterogeneous landscape of quantified 
outcomes across all RCTs and cohort-control studies 
for SCS in FBSS patients. Consequently, in our analysis 
we could not combine data to generate consolidated 
numerical evidence. The data is therefore presented 
individually and then synthesized.
Results
The Literature search identified 57 publications, 
of which 46 were excluded due to duplications and 
inclusion/exclusion criteria, yielding a total of 11 
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Analgesic use
Seven studies included changes in analgesic use as 
a secondary outcome [8,10-11,14,16-18]. Two studies 
reported a statistically significant improvement in 
overall analgesic use: North, et al. reported significantly 
lower opioid use within the SCS group than the re-
operation group (p = 0.025), while van Gorp, et al. 
reported a decrease in Medication Quantification Scale 
(MQS) from 14.0 to 11.4 within the SCS and PFNS group 
(p = 0.017) without mention of the effects of SCS alone 
[8,16]. One study showed significant reduction only 
in anticonvulsant use (odds ratio = 0.35, p = 0.02) at 
6mo follow-up [14]. Other drug categories in the study 
(opioids, NSAIDs, antidepressants) demonstrated similar 
downward trends. At 24 months follow-up, opioids and 
anticonvulsants continued to trend downward, though 
this was not statistically significant [10]. Turner, et al. 
results suggested an initial statistically insignificant 
improvement that was lost by 12 months [11]. In North, 
et al.’s study, the number of electrodes placed did not 
significantly change analgesic use (41% decreased use, 
53% increased use) [18]; however, electrode placement 
did produce change - 75% of patients with laminectomy 
vs. 33% with percutaneous placement achieved a 
reduction in prescription analgesic use [17]. The level of 
the reduction was not mentioned.
Functional Change
Nine studies included functional change as a second-
ary outcome [8,10,11,13-18]. A study comparing con-
ventional medicine to SCS reported statistically signifi-
cant reduction in Oswestry Disability Index (ODI) from 
56.1 to 44.9 (p < 0.001) at 6 months and 59 to 47 (p < 
0.0002) at 24 months [10]. ODI scores reduced similarly 
with SCS burst treatment in a study comparing place-
bo, burst, and 500 Hz stimulation (baseline 22.3, burst 
19.2) [13]. Comparing re-operation to SCS, there was a 
greater net loss of function in patients who underwent 
re-operation, while SCS patients always experienced 
a net functional gain [8]. In a study comparing single 
to dual electrode placement, most study participants 
across both groups did not experience impairment in 
activities of daily living; however, 53% of the total study 
population experienced decreased strength or coor-
dination and 12% experienced decreased bladder or 
bowel control (p-value not provided) [18]. One study 
comparing laminectomy to percutaneous electrode 
placement reported that laminectomy electrodes sup-
ported greater net functional improvement over percu-
taneous electrodes [17]. No statistically significant dif-
ference in function was found when comparing SCS to 
conventional treatment options among workers’ com-
pensation patients at 12 and 24 months follow-up [11]. 
In a comparison between conventional stimulation and 
high frequency stimulation, both showed significant re-
all groups (sham, 1200 Hz, 3030 Hz, and 5882 Hz) from 
baseline, p < 0.001, with only one frequency (5882 Hz) 
in pair-wise analysis being superior to sham. Notably, 
this study revealed a significant placebo component to 
high frequency stimulation, complicating prior study 
results and necessitating further research into this area.
Two out of five studies with axial or radiating pain re-
lief as their primary outcome showed statistically signifi-
cant improvement with SCS treatment [8,16]; one study 
showed clinically significant improvement without sta-
tistical significance [17]; and, two studies did not report 
significance for the final follow-up, though one provid-
ed evidence for significant pain relief at an earlier fol-
low-up interval [12,15]. The follow-up period for these 
studies ranged from 2 weeks to 3 years. North, et al. 
compared SCS implantation in FBSS patients to standard 
re-operation [8]. At a 3 year follow-up, they found that 
47% of post-implantation SCS cohort patients achieved 
50% pain reduction and were satisfied with their re-
sults, compared with 12% of the re-operation cohort (p 
< 0.01). In a later study in 2005, North, et al. looked at 
the efficacy of percutaneous vs. laminectomy electrode 
placement [17]. At the 1.9 year follow-up, 83% of pa-
tients with laminectomy electrodes and 42% of patients 
with percutaneous electrodes had at least 50% pain 
relief (p < 0.05). At 2.9 years follow-up, they found no 
statistically significant difference in pain relief between 
groups, but showed at least a 50% pain reduction in 42% 
of laminectomy implants and 25% of percutaneous im-
plants (authors did not provide a p-value, but noted this 
finding to be statistically insignificant). Van Havenbergh, 
et al. studied the efficacy of 500 Hz vs. 1000 Hz burst 
stimulation for pain relief and found no significant dif-
ference between the two frequencies for back pain (p 
= 0.90), limb pain (p = 0.76), or general pain (p = 0.55); 
however, they did show an overall Visual Analogue 
Scale (VAS) reduction to 5/10 from baseline - though, 
notably, baseline was not reported and a p-value was 
not given [12]. Van Gorp, et al. looked at patients who 
had adequate leg pain relief, but inadequate back pain 
relief with SCS, and added peripheral nerve field stimu-
lation (PNFS) to observe the effects on back pain [16]. 
At 12 months follow-up, they concluded that PNFS plus 
SCS provides superior back pain relief than SCS alone 
(p < 0.001) - on the VAS scale, back pain with SCS re-
duced from a mean of 73.9 to 68.3 (p < 0.001), and leg 
pain reduced from a mean of 71.8 to 12.9 (p < 0.001) 
at 3 months follow-up (prior to adding PNFS to the SCS 
treatment). De Andres, et al. compared conventional 
SCS to high frequency SCS (HFSCS) and noted a clinical-
ly significant reduction in pain for both groups (20-25% 
reduction in average Numerical Rating Scale (NRS) score 
at 1 year) [15]. This was not statistically significant (p = 
0.560) and there was no significant difference between 
groups (p = 0.11).
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believed that 5882 Hz stimulation provided consider-
able improvement; however, among those who were 
very satisfied or somewhat satisfied with the therapy, 
there was no statistically significant difference between 
sham (63%), 1200 Hz (63%), 3030 Hz (75%), and 5882 Hz 
(75%) (p = 0.672) [9].
Patient Selection Consideration Overview
In this review, most studies focused on patient 
selections considerations such as patient sex, age, 
number of prior lumbar surgeries, time since last 
surgery, and location of pain. Our goal was to determine 
whether there is evidence for additional considerations 
for patient selection, specifically working status, 
psychological health, smoking status, sex and race. Six 
studies included working status and 3 studies included 
patients with worker’s compensation [8,10,11,17,18]; 
5 studies did not mention working status or worker’s 
compensation. Six studies included psychological pre-
testing for all patients and one study pre-screened 
only 25% of the SCS cohort [8,9,11,13-16]. Zero studies 
included information on patient race or smoking status.
Working Status
Six studies included work status as a patient de-
scriptor with only three reporting inclusion of workers’ 
compensation patients [8,10,11,14,17,18]. Comparing 
re-operation to SCS implantation, North, et al. in Jan 
2005, found that there was no significant difference in a 
patient’s ability to return to work [8]. North, et al. in Nov 
2005, reported that two patients who pre-operatively 
were unable to work due to their pain returned to work 
post-operatively, while another patient moved from 
part-time to full-time post-operatively [17]. In looking at 
CMM vs. SCS and CMM, Kumar, et al. also found that 
there were no significant return-to-work differences be-
tween the two groups; however, it was noted that at 24 
months follow-up 5 patients in the SCS group returned 
to work (4 of which had been out of work for a mean of 
> 2.5 years) while 2 patients stopped working without 
further explanation [10,14]. Turner, et al. analyzed the 
level of SCS benefit in workers’ compensation patients 
in Washington State and found there is no evidence for 
statistically significant benefit overall [11]. Turner, et al. 
also concluded that there is not a significant benefit for 
improving pain or function in this population. All other 
studies did not comment on pain improvement in this 
specific patient subset.
Psychological Health
In this review, eight out of eleven studies definitively 
included mental health pre-screening [8-11,13-15]. In 
contrast, mental health was not mentioned in the three 
remaining studies [12,17,18]. Seven of these studies 
reported active and/or untreated psychiatric disorders 
as grounds for exclusion [8-10,13-15]. No studies 
duction in ODI with no between-group differences [15]. 
Van Gorp, et al. did not report on ODI outcomes for SCS 
alone vs. baseline [16].
Quality of Life
Six studies included changes in quality of life as a 
secondary outcome; five of the six used validated tools: 
Short Form-36 (SF-36), Short Form-12 (SF-12), EuroQoL 
five dimensional (EQ-5D) index, and the Pain Vigilance 
and Awareness Questionnaire (PVAQ) [10,12,14-
16,18]. Four studies reported a statistically significant 
improvement in overall quality of life [10,14-16]. The 
PROCESS study showed increased quality of life in 
the SCS group compared to the conventional medical 
management group at 6 months (SF-36: 7 of 8 health-
related quality of life measures were enhanced, p < 
0.02; EQ-5D: differential improvement from baseline 
of 0.23) and at 24 months (SF-36: 7 of 8 health-related 
quality of life measures were enhanced, p < 0.01; 
EQ-5D improved by about 0.30 from baseline, p < 
0.0001) [10,14]. While van Gorp, et al. demonstrated 
the superior functional improvement of SCS with the 
addition of PFNS (as assessed by SF-36), they did not 
report data for SCS alone [16]. Van Havenbergh, et al. 
used SF-36 and PVAQ to report no significant difference 
in quality of life between 500 Hz burst stimulation and 
1000 Hz burst stimulation; however, the authors did not 
provide a reference to baseline data [12]. De Andres 
showed that both conventional and HFSCS provided 
significant quality of life improvement in all domains, as 
per the SF-12 form [15].
Patient Satisfaction
Eight studies included patient satisfaction as a sec-
ondary outcome [8-10,13-17]. Six reported a favorable 
patient response toward SCS treatment, with two stud-
ies revealing that patients would prefer either under-
going SCS implantation again or undergoing the im-
plantation in place of another back surgery if given the 
choice [8-10,13-17].  The 2007 Kumar study concluded 
that 66% of patients receiving SCS were satisfied with 
their pain relief, while 86% were satisfied with treat-
ment overall (p < 0.001) [14]. In the 2008 Kumar, et al. 
study, it was noted that 66% of patients receiving SCS 
were satisfied with pain relief, while 93% were satisfied 
with the treatment overall (p-value not reported) [10]. 
Schu, et al. reported that 80% of patients preferred 
burst stimulation above other forms of stimulation (p 
= 0.0004) [13]. Van Gorp, et al. reported mean Patient 
Global Impression of Change (PGIC) at 12 months as 3.3, 
indicating an impression of minimal to moderate recov-
ery [16]. De Andres, et al. reported that both conven-
tional stimulation and HFSCS had significant improve-
ment in PGIC (increase of 0.6-0.9); but, they were not 
statistically different from each other [15]. Al-Kaisy, et 
al. reported that PGIC scores showed that most patients 
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levels [21]. These studies suggest that work status may 
be insufficient unto itself for understanding patient out-
comes, calling for a more nuanced approach to patient 
selection within this category.  Overall, the studies ex-
amined suggest that SCS treatment likely positively in-
fluences patients’ ability to return to work. This is con-
sistent with the data presented in a recent meta-anal-
ysis [22]. The Turner, et al. study [11] - which did not 
find significant pain relief with SCS compared to medical 
therapy in the workers’ compensation population - had 
a few issues of note.  First, it was a cohort study with 
matched controls instead of a randomized controlled 
study.  Second, the population included in the study 
tended to have more severe pain and for longer peri-
ods of time than those of other studies, which makes 
it less generalizable. And lastly, patients who had failed 
SCS trials were eventually also included in the long term 
analysis of the data. 
Psychological Health
The impact of mental health on pain treatment re-
sponse has been well documented in the literature. 
Notably, in a 2009 review, psychological characteristics 
such as depression, anxiety, somatization, and poor 
coping were deemed as relevant predictors for poorer 
outcomes after device implantation [23]. A 2016 study 
added that the chosen outcomes in a study, such as 
functionality or pain catastrophizing, impact which psy-
chiatric factors are important for screening in a study 
population [24]. Thus, screening for the psychiatric 
co-morbidities that correlate with the desired outcome 
measures is important for more accurate predictions 
of treatment outcome and is certainly an area that de-
serves further research. Overall, it is now standard of 
care in most practices to include psychological testing as 
a screening test for SCS implantation. Of note, the Turn-
er, et al. study [11] included patients with lower scores 
showing worse psychological status, which may have 
contributed to the negative result of the study.
Smoking Status
Various studies have shown that smoking status im-
pacts chronic pain treatment outcomes. Fishbain, et 
al. observed the impact of smoking status on a cohort 
of patients with chronic low back pain, citing that pain 
outcomes were worse among smokers regardless of fol-
low-up time period [25]. Additionally, Hooten, et al. an-
alyzed the effects of smoking on multidisciplinary pain 
rehabilitation program efficacy and found that smokers 
had worse outcomes with respect to some adjunctive 
modifiers of pain, notably pain catastrophizing and de-
pression [26]. However, none of the studies included in 
this review provided subgroup analysis regarding the 
impact of smoking status on the success of SCS implant 
for FBSS. This remains a knowledge gap that is in need 
of further investigation.
compared psychiatric status to pain outcomes except 
Turner, et al. who found that patients with higher 
mental health screening scores (indicating healthier 
psychiatric status) had significantly better outcomes 
with respect to pain than those with lower scores [11]. 
Notably, Turner, et al. screened only 25% of patients in 
the SCS group and none in the Pain Clinic group.
Smoking Status
None of the studies in this review reported on the 
efficacy of SCS in relationship to smoking status.
Sex
All eleven studies reported baseline sex 
characteristics of participants; however, outcome data 
was not disaggregated according to sex in any study [8-
18].
Race
None of the studies in this review reported on the 
efficacy of SCS in relationship to race.
Discussion
Since the first trials of spinal cord stimulation for 
chronic pain, there have been significant advancements 
in SCS delivery. Our understanding of its therapeutic 
capacity as well as its limitations has continued to 
evolve. The evidence found within the body of research 
investigated in this systematic review on spinal cord 
stimulation for FBSS showed that the results are 
mixed; but, they overall seem to suggest that SCS is 
likely efficacious for the short term relief of pain from 
FBSS. Based on the current available highest level 
evidence (ie randomized controlled studies vs. cohort 
studies of matched controls), pain relief from SCS is 
generally better than pain relief achieved with repeat 
back surgery or medical management. Pain relief is 
more likely achieved with SCS for those with leg pain 
as the predominant symptom versus those with axial 
back pain. In addition, a higher percentage of patients 
seem to report pain relief earlier in the follow up period 
(ie months after implant) compared to later (ie years 
after implant). This is especially important for further 
clarification, as at least one study reported a similar 
level of pain relief between high-frequency spinal cord 
stimulation and placebo [12].
Working Status
Work-related injuries impacting work status charac-
terize an important subgroup of patients with low back 
pain. Some studies have suggested that those receiving 
Workers’ Compensation experience worse pain out-
comes overall regardless of treatment [19,20]. This has 
been challenged with evidence that it is specifically pa-
tient return-to-work expectations and the time required 
before returning to work that significantly affects pain 
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SCS implant for FBSS. This remains a knowledge gap that 
is in need of further investigation (Table 1).
Race
Race has routinely been included as a variable in 
contemporary scientific inquiry. To continue in this 
tradition the category was included in our review. 
However, the utility of race itself as a measure of 
analysis can be called into question when assessing 
responses to pain treatment. Race is a fluid and evolving 
sociopolitical category with limited biologic significance 
[30-33]. Racial groups themselves are heterogeneous 
making intra-race variability an important consideration 
for the accuracy and generalizability of race-based 
results [34]. And while racial disparities with respect to 
the epidemiology, access, and experience of pain have 
Sex
A comprehensive 2009 review by Fillingim, et al. 
looked at differences in the prevalence of pain between 
men and women in numerous forms and settings [27]. 
They concluded that of the most common forms of pain, 
women experience a higher prevalence and intensity of 
pain than men. With respect to analgesic response, a 
meta-analysis by Niesters, et al. reported that there is 
inconclusive evidence for differences in opioid response 
between men and women [28]. Yet, differences in 
non-analgesic treatment responses between sexes 
were noted in Kheog, et al.’s study, which observed 
significantly more pain and catastrophizing among post-
treatment women after 3 months [29]. However, none 
of the studies included in this review provided subgroup 
analysis regarding the impact of sex on the success of 
Table 1: Characteristics, quality, and main outcomes of included studies.
Study Study Design Study size Jadad Scale Summary of Findings
North, Jan 
2005 [8]
RCT 50 3 SCS provides greater pain relief and patient satisfaction with 
less analgesic use and loss of function than re-operation for 
treatment of chronic radicular pain after prior lumbosacral spine 
surgery
North, June 
2005 [18]
Prospective, 
controlled
20 0 Improved pain relief and reduction in analgesic use achieved in 
both single and double electrode groups
North, Nov 
2005 [17]
RCT 24 1 Both laminectomy and percutaneous electrode placement 
achieved significant axial and radial pain relief
Kumar, 2007 
[14]
RCT 100 3 SCS and CMM is more effective at pain reduction, improved 
function, and health-related quality of life than CMM alone at 
6mo follow-up with greater patient satisfaction
Kumar, 2008 
[10]
RCT 46 3 SCS and CMM is more effective at pain reduction, improved 
function, and health-related quality of life than CMM alone at 
24mo follow-up with greater patient satisfaction
Turner, 2009 
[11]
Prospective, 
population-based 
controlled cohort 
study
168 0 No evidence for greater success* of SCS over pain clinic or 
usual care in workers’ compensation patients with FBSS after 
6mo. No change in function or analgesic use
Schu, 2014 
[13]
Randomized, 
double-blind, 
placebo controlled 
study
20 5 Burst stimulation provided significantly greater pain relief 
over 500 Hz tonic stimulation and placebo stimulation. No 
statistically significant improvement between groups in function. 
High patient satisfaction with burst stim
Van 
Havenbergh, 
2014 [12]
RCT 15 2 Reduction in axial and radial pain, significance not stated. 
No significant difference in pain relief between 500 Hz burst 
stimulation and 1000 Hz burst stimulation
van Gorp, 
2017 [16]
RCT 52 2 SCS vs. SCS + PNFS: Significant improvement in axial 
and radial pain for SCS alone. Minimal to moderate patient 
impression of improvement overall
de Andres, 
2017 [15]
RCT 60 5 Conventional vs. HFSCS: Statistically significant improvement 
in axial and radial pain long term and improved quality of life. 
High patient satisfaction.
Al-Kaisy, 
2018 [9]
Prospective, 
randomized, sham-
controlled, double-
blinded, crossover 
study
24 5 Sham vs. array of HFSCS: Statistically significant pain relief 
in all groups, including sham. Moderate patient satisfaction; 
similar between all groups
RCT = randomized controlled trial; SCS = spinal cord stimulation; CMC = conventional medical management; PNFS = peripheral 
nerve field stimulation; HFSCS=high frequency spinal cord stimulation; mo= months; *Success was defined as: > 50% pain relief 
+ at least 2-point reduction on RDQ score + reduction in daily opioid medication use
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Table 2: Jadad Scale [7].
Jadad scale for reporting randomized controlled trials
Item Maximum points Description
Randomization 2 1 point if randomization is mentioned
1 additional point if the method of randomization is appropriate
Deduct 1 point if the method of randomization is inappropriate 
(minimum 0)
Blinding 2 1 point if blinding is mentioned 
1 additional point if the method of blinding is appropriate
Deduct 1 point if the method of blinding is inappropriate 
(minimum 0)
An account of all patients 1 The fate of all patients in the trial is known. If there are no data 
the reason is stated
been reported in the literature, more recent studies 
have concluded that racial health disparities generally 
exist as consequences of racism, rather than race itself 
[35-39]. In a 2009 review on racial disparities in pain, 
Anderson, et al. concludes that studies should control 
for variables such as discrimination, immigration, the 
process of acculturation, health status, education, 
occupation, income, neighborhood socioeconomic 
level, and language of choice, among others [34]. 
Analyzing data from 13,777 patients, Reyes-Gibby, et al. 
found that significant predictors for racial differences 
in pain severity included chronic disease, psychosocial 
distress, Medicaid insurance, and lower education level 
[40]. Thus, assessing a multitude of factors associated 
with the nuanced consequences of racism in its various 
forms (internalized, interpersonal, institutional [41]) 
rather than the imprecise and outdated categories of 
race would facilitate more accurate analyses of pain 
treatment outcomes. However, none of the studies 
included in this review provided subgroup analysis 
regarding the impact of these variables on the success 
of SCS for FBSS. This remains a knowledge gap that is in 
need of further investigation.
Limitations
Limitations for this systematic review include a low 
volume of studies available for review as well as the 
inability to consolidate data due to the heterogeneity 
of quantitative analysis tools between studies. Individ-
ual study limitations chiefly remain the inability to com-
pare outcomes to a placebo group until the advent of 
more advanced delivery methods. Only 3 studies were 
of high quality as assessed by the Jadad scale [9,13,15]. 
Further, the patient characteristics assessed were not 
exhaustive and there are additional patient character-
istics that can affect treatment outcomes that were not 
mentioned in this review (Table 2).
Study Bias
Importantly, seven out of the eleven studies re-
viewed had sources of potential funding or affilia-
tion bias [8-14]. Four studies used Medtronic devices 
and were simultaneously funded and/or managed by 
Medtronic [9-11,14]. Authors involved in the PROCESS 
study were also receiving financial reimbursements 
from Medtronic for consultancy work [10,14]. Two au-
thors listed on the Schu, et al. paper received a research 
fellowship grant from, and served as consultants for, St. 
Jude Medical - the device manufacturer for their study 
[13]. Two authors for the Al-Kaisy [9] study received 
sponsorship and speaker fees from Medtronic, while 
two different authors on the same study are Medtronic 
employees. Van Havenbergh’s study was not funded by 
St. Jude Medical; however, one of the authors is a St. 
Jude employee [12]. Turner, et al.’s study was funded by 
the Washington State Department of Labor and Indus-
tries, which pays for Washington state workers’ com-
pensation insurance [11].
Two studies denied or minimized any potential con-
flicts of interest [15,16]. De Andres specifically noted 
having independent funding sources with active mini-
mization of the role of manufacturing representatives 
in the study [15].
Two studies did not disclose whether or not con-
flicts might have existed [8,17].
Conclusion
FBSS is now one of the most common indications 
for the utilization of SCS.  Evidence for the efficacy of 
SCS in this indication is accumulating, with most studies 
demonstrating its efficacy - especially for those patients 
with leg pain as the predominant symptom.  However, 
a significant weakness in the current available data in-
cludes potential bias based on the funding source for 
most studies. Additionally, it is clear that SCS provides 
short-term benefit, yet there is no solid evidence that 
SCS provides any benefit beyond two years of implanta-
tion.  Another major concern of SCS is its significant pla-
cebo effect, which makes the true therapeutic response 
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in patients with failed back surgery syndrome. Pain. 2007; 
132:179-188.
15. De Andres J, Monsalve-Dolz V, Fabregat-Cid G, et al. 
Prospective, randomized blind effect-on-outcome study of 
conventional vs high-frequency spinal cord stimulation in 
patients with pain and disability due to failed back surgery 
syndrome. Pain medicine (Malden, Mass.). 2017; 18:2401-
2421.
16. van Gorp, Eric-Jan J. A. A, Teernstra O, Aukes HJ, et al. 
Long-term effect of peripheral nerve field stimulation as add-
on therapy to spinal cord stimulation to treat low back pain in 
failed back surgery syndrome patients: A 12-month follow-
up of a randomized controlled study. Neuromodulation: 
Technology at the Neural Interface. 2018 .
17. North RB, Kidd DH, Petrucci L, Dorsi MJ. Spinal cord 
stimulation electrode design: A prospective, randomized, 
controlled trial comparing percutaneous with laminectomy 
electrodes: Part II-clinical outcomes. Neurosurgery. 2005; 
57:990-996.
18. North RB, Kidd DH, Olin J, Sieracki JN, Petrucci L. Spinal 
cord stimulation for axial low back pain: A prospective 
controlled trial comparing 16-contact insulated electrodes 
with 4-contact percutaneous electrodes. Neuromodulation : 
journal of the International Neuromodulation Society. 2006; 
9:56.
19. Simon, Jeremy, MD|McAuliffe, Matthew, MD|Shamim, 
Fehreen, MD|Vuong, Nancy, MD|Tahaei, Amir, MD. 
Discogenic low back pain. Physical Medicine and 
Rehabilitation Clinics of North America. 2014; 25:305-317.
20. Harris I, Mulford J, Solomon M, van Gelder JM, Young J. 
Association between compensation status and outcome 
after surgery: A meta-analysis. JAMA. 2005; 293:1644-
1652.
21. Gross DP, Battie MC. Work-related recovery expectations 
and the prognosis of chronic low back pain within a workers' 
compensation setting. J Occup Environ Med. 2005; 47:428-
433.
22. Moens M, Goudman L, Brouns R, et al. Return to work of 
patients treated with spinal cord stimulation for chronic pain: 
A systematic review and meta-analysis. Neuromodulation. 
2018; .
23. Celestin J, Edwards RR, Jamison RN. Pretreatment 
psychosocial variables as predictors of outcomes following 
lumbar surgery and spinal cord stimulation: A systematic 
review and literature synthesis. Pain medicine (Malden, 
Mass.). 2009; 10:639-653.
24. Fama CA, Chen N, Prusik J, et al. The use of preoperative 
psychological evaluations to predict spinal cord stimulation 
success: Our experience and a review of the literature. 
Neuromodulation: Technology at the Neural Interface. 
2016; 19:429-436.
25. Fishbain DA, Lewis JE, Cutler R, Cole B, Steele Rosomoff R, 
Rosomoff HL. Does smoking status affect multidisciplinary 
pain facility treatment outcome? Pain Medicine. 2008; 
9:1081-1090.
26. Hooten WM, Townsend CO, Bruce BK, et al. Effects of 
smoking status on immediate treatment outcomes of 
multidisciplinary pain rehabilitation. Pain medicine (Malden, 
Mass.). 2009; 10:347-355.
27. Fillingim, Roger B.|King, Christopher D.|Ribeiro-Dasilva, 
Margarete C.|Rahim-Williams, Bridgett|Riley, Joseph 
difficult to judge.  Further, it is increasingly important 
to focus future studies on accurately identifying the 
patient populations that will best respond to both SCS 
therapy in general as well as specific stimulation tech-
niques.
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